The Gaithersburg company, which has a manufacturing site in Frederick , had an order for 13 million doses earlier this year. The total doses with the new order will bring the contract to about $453 million.
Tor Constantino, a MedImmune spokesman, said the vaccine is made at the company's laboratories in the United Kingdom, shipped to a manufacturing site near Philadelphia and stored in Kentucky, from where it is distributed.
The Frederick facility manufactures Synagis, a medication for childhood respiratory problems.
The nasal spray H1N1 vaccine can be used by individuals ages 2 to 49, according to MedImmune.
"We will continue to work collaboratively with the U.S. government and public health authorities to contribute to the response to this unpredictable infectious disease," MedImmune President Tony Zook said.
The live attenuated influenza vaccine is different from the injected influenza vaccine, or flu shot, in that it contains live vaccine virus strains that are weakened so as not to cause the flu.
It is delivered into the nose, where the influenza virus usually enters the body, rather than by injection.
It prompts the body to begin mounting an immune response after the first dose.
MedImmune's influenza vaccines are licensed only in the United States.
MedImmune is the biologics business of AstraZeneca.
To see more of the Frederick News-Post or to subscribe to the newspaper, go to http://www.fredericknewspost.com. Copyright (c) 2009, The Frederick News-Post, Md. Distributed by McClatchy-Tribune Information Services. For reprints, email tmsreprints@permissionsgroup.com, call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index